Financial Architects (New Jersey)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
-600
Closed -$10K 1568
2018
Q2
$10K Hold
600
﹤0.01% 1006
2018
Q1
$9K Hold
600
﹤0.01% 1134
2017
Q4
$9K Hold
600
﹤0.01% 1187
2017
Q3
$8K Hold
600
﹤0.01% 1199
2017
Q2
$7K Sell
600
-97
-14% -$1.21K ﹤0.01% 1226
2017
Q1
$10K Hold
697
﹤0.01% 1150
2016
Q4
$12K Buy
+697
New +$12.6K ﹤0.01% 975
2015
Q3
Sell
-46
Closed -$2K 1069
2015
Q2
$2K Buy
+46
New +$1.4K ﹤0.01% 1132

Other funds holding HZNP

Financial Architects (New Jersey)'s HZNP Position: Q3 2018 in Review

Financial Architects (New Jersey) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2018, closing a stake of 600 shares — an estimated $10K sold.

Financial Architects (New Jersey) first reported a position in HZNP in Q2 2015 and held it in 8 quarters. The position peaked at $12K in Q4 2016. 221 funds tracked by Wall St. Rank hold HZNP as of Q3 2018.

  • Financial Architects (New Jersey) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 600 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2018, an estimated $10K.
  • Financial Architects (New Jersey) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 8 quarters.
  • Financial Architects (New Jersey)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $12K in Q4 2016.
  • 221 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2018, filed 29 Oct 2018.